Feed NXTC
NX

NextCure, Inc.

NXTC · NASDAQ

$6.02 +2.56% (+$0.15)
1M +3.90%
Market Cap $21.7M
P/E Ratio -
Div. Yield -
ROE 175.46%

Bulios Fair Price

$6.89

14.5% upside

Current Price

$6.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NXTC is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
1/9
Valuation
93 /100
Cheap
P/B 1.79x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 40.70%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 259.91%
ROE 175.46%
ROA 188.98%
Debt
97 /100
Low
Debt/Equity 0.35x
Current ratio 3.47x
Int. coverage N/A
Stability
61 /100
Moderate
Beta 1.34x
EPS volatility 3.16%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NXTC
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Michael S. Richman

Employees

40

Headquarters

Beltsville

Upcoming events

04 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.